Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 7/20 | 0.57 |
| ▸ | PRSS2 | P07478 | 5/20 | 0.57 |
| ▸ | PRSS3 | P35030 | 5/20 | 0.57 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.57 |
| ▸ | F10 | P00742 | 1/20 | 0.57 |
| ▸ | NOS3 | P29474 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 1/20 | 0.52 |
| ▸ | NOS2 | P35228 | 1/20 | 0.52 |
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.48 |
| ▸ | F2 | P00734 | 3/20 | 0.48 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | C1S | P09871 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MASP2 | O00187 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10925472 | 0.85 | F2 (0.76) | PRSS1PRSS2PRSS3ST14F2 | |
| SCHEMBL20880153 | 0.84 | PRSS1 (0.53) | PRSS1PRSS2PRSS3LOXL2F10 | |
| SCHEMBL20880131 | 0.80 | NOS1 (0.44) | PRSS1PRSS2PRSS3LOXL2F10 | |
| SCHEMBL15373362 | 0.80 | ST14 (0.62) | PRSS1PRSS2PRSS3LOXL2F10 | |
| SCHEMBL13714812 | 0.80 | PRSS1 (0.53) | PRSS1PRSS2PRSS3LOXL2F10 | |
| SCHEMBL2717268 | 0.80 | PRSS1 (0.70) | PRSS1PRSS2PRSS3LOXL2F10 | |
| SCHEMBL22872694 | 0.79 | NOS1 (0.52) | LOXL2NOS3NOS1NOS2LMNA | |
| SCHEMBL10211024 | 0.79 | PRSS1 (0.57) | PRSS1PRSS2PRSS3LOXL2F10 | |
| SCHEMBL3882642 | 0.79 | PLA2G10 (0.57) | LOXL2NOS3NOS1NOS2 | |
| SCHEMBL16181585 | 0.79 | NOS1 (0.52) | PRSS1LOXL2NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021113682-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| EP-3466961-A1 | PROLINAMIDE DERIVATIVE AS THROMBIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF | Li, Min (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-9434760-B2 | Prolinamide derivatives as thrombin inhibitors, preparation method and application thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2016-09-06 | — | — | US | disclosed |
| EP-2824097-A1 | Prolinamide derivative as thrombin inhibitor, preparation method and application thereof | Shanghai Institute of Pharmaceutical Industry (CN) | 2015-01-14 | — | — | EP | disclosed |
| EP-2349312-B1 | N-TERMINALLY MODIFIED TETRAPEPTIDE DERIVATIVES HAVING A C-TERMINAL ARGININE MIMETIC | PHILIPPS UNIVERSITÄT MARBURG (DE) | 2014-06-04 | — | — | EP | disclosed |
| US-20130296245-A1 | PROLINAMIADE DERIVATIVES AS THROMBIN INHIBITOR, PREPRARATION METHOD AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2013-11-07 | — | — | US | disclosed |
| EP-2639230-A1 | PROLINAMIDE DERIVATIVE AS THROMBIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Institute of Pharmaceutical Industry (CN) | 2013-09-18 | — | — | EP | disclosed |
| WO-2013029182-A1 | STABLE PEPTIDE-BASED FURIN INHIBITORS | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2013-03-07 | — | — | WO | disclosed |
| US-8129547-B2 | Anticoagulation of human blood ex vivo | HELLSTERN PETER (DE) | 2012-03-06 | — | — | US | disclosed |
| US-8129547-B2 | Anticoagulation of human blood ex vivo | HELLSTERN PETER (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20100280412-A1 | Anticoagulation Of Human Blood Ex Vivo | HELLSTERN PETER | 2010-11-04 | — | — | US | disclosed |
| US-20100280412-A1 | Anticoagulation Of Human Blood Ex Vivo | HELLSTERN PETER | 2010-11-04 | — | — | US | disclosed |
| EP-1355674-B1 | OLIGO ALKYLENE GLYCOL OR POLYALKYLENE GLYCOL-COUPLED THROMBIN INHIBITORS | JENAFFIN GMBH (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-7407982-B2 | Oligo or polyalkylene glycol-coupled thrombin inhibitors | HAEMOSYS GMBH (DE) | 2008-08-05 | — | — | US | disclosed |
| US-7407982-B2 | Oligo or polyalkylene glycol-coupled thrombin inhibitors | HAEMOSYS GMBH (DE) | 2008-08-05 | — | — | US | disclosed |
| WO-2007085461-A2 | ANTICOAGULATION OF HUMAN BLOOD EX VIVO | STÜRZEBECHER, Uta (DE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296245-A1 | PROLINAMIADE DERIVATIVES AS THROMBIN INHIBITOR, PREPRARATION METHOD AND APPLICATION THEREOF | PREP, TFPI, PEPD | PRSS1 36/4885PRSS2 78/4885PRSS3 115/4885 |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | PRSS1 2685/4885PRSS2 2842/4885PRSS3 2974/4885 |
| US-20100280412-A1 | Anticoagulation Of Human Blood Ex Vivo | F5, TFPI, F11 | PRSS1 350/4885PRSS2 328/4885PRSS3 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.